S80 New Approaches and Outcomes to Targeted Therapies in Thyroid Cancer

Program: Symposia
Clinical Session
Sunday, March 8, 2015: 2:15 PM-3:45 PM
Room 20A (San Diego Convention Center)
**This session is eligible for CME credit**

Supported by Astra Zeneca LP

Chair:
Angela M. Leung, UCLA David Geffen School of Medicine, Los Angeles, CA

Nothing to Disclose: AML

The results of Phase 3 trials with therapies that target specific signal transduction pathways in differentatiated thyroid cancer are becoming available to guide clinical care. Treatment of papillary thyroid cancer, medullary cancer, and salvage therapy in patients that fail tyrosine kinase inhibitors will be presented.

2:15 PM
Manisha H Shah, MD, Division of Medical Oncology, Ohio State University Comprehensive Cancer Center, Columbus, OH
Disclosure: MHS: Principal Investigator, Eisai, Principal Investigator, Exelixis, Inc..
2:45 PM
Ezra Cohen, MD, UCSD
Disclosure: EC: Ad Hoc Consultant, Bayer, Inc., Ad Hoc Consultant, Eisai, Ad Hoc Consultant, Exelixis, Inc..
3:15 PM
Maria E Cabanillas, M.D., Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Disclosure: MEC: Advisory Group Member, Exelixis, Inc., Investigator, Exelixis, Inc., Advisory Group Member, Eisai, Investigator, Eisai, Investigator, Genentech, Inc..
See more of: Symposia